Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a…
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Amicus Therapeutics Reports Preliminary 2023 Revenue And Provides 2024 Strategic Outlook; Q4 Revenue ~$115.1M Vs $112.25M Est.; Sees FY23 Revenue Of ~$399.4M Vs $396.45M Est.; Co Sees FY24 As First Full Year Of Achieving Non-GAAP Profitability
Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "Last year was an incredible year for Amicus highlighted by the continued double-digit growth of Galafold sales and the global
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Analysts have provided the following ratings for Amicus Therapeutics (NASDAQ:FOLD) within the last quarter: Bullish Somewhat Bullish Indifferent…
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell
• Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
Amicus Therapeutics And Blackstone Enter Into $430M Strategic Financing Collaboration; Blackstone To Also Purchase $30M Of Amicus Common Stock
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common StockPRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday’s Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Brooge Energy Limited (NASDAQ: BROG) shares surged 23% to $6.64 in pre-market trading after gaining 7% on Thursday.
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.
Amicus Therapeutics Announces FDA Approval And Launch Of New Treatment For Pompe Disease
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe DiseaseAmicus
Fabry Disease Treatment Showdown: Protalix Bio’s Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult